Breast Cancer
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Breast cancer patients who participated in the phase I study DS8201-A-J101 or phase II study DS8201-A-U201 in Japan and received at least one dose of T-DXd. 2. Patients who have not withdrawn their consent at the time of participating in the phase I study DS8201-A-J101 or phase II study DS8201-A-U201. 3. Patients who have had chest computed tomography examinations (including pre-dose) during T-DXd administration in the Phase I study DS8201-A-J101 or Phase II study DS8201-A-U201, and their CT images and information collected up to the cut-off date of February 1, 2019 in DS8201-A-J101 and March 21, 2019 in DS-8201-A-U201 have been stored at Daiichi Sankyo Co., Ltd. and its contractors.
Exclusion criteria
Exclusion criteria: Patients who expressed non-participation in the study by the person or representative before fixing the data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnosis accuracy rates (sensitivity, specificity, accuracy, positive predictive value, and negative predictive value) of AIQCT for T-DXd-related ILD. | — |
Secondary
| Measure | Time frame |
|---|---|
| Physician's diagnostic accuracy rates for T-DXd -related ILD with and without AIQCT assistance. | — |
Countries
Japan
Contacts
KYOTO UNIVERSITY Department of Rehabilitation